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Introduction {#sec001}
============

*Staphylococcus aureus* is a leading cause of community- and healthcare-associated infections. It is a pathogenic organism capable of causing a range of infections. This is due to its ability to express multiple virulence factors and harbour multiple antimicrobial resistance determinants \[[@pone.0225726.ref001], [@pone.0225726.ref002]\]. The Panton-Valentine Leukocidin (PVL) exotoxin is a pore-forming cytotoxic exoprotein encoded by the bicomponent *luk*S-PV and *luk*F-PV genes, which are carried on a bacteriophage \[[@pone.0225726.ref003]\]. PVL targets cells of the human immune system and causes cell death. Isolates of *S*. *aureus* harbouring PVL are often due to community-associated infections \[[@pone.0225726.ref004]\] and have been linked to more severe clinical manifestations such as necrotising pneumonia, severe bone and joint infections and skin and soft tissue infections often requiring surgical drainage \[[@pone.0225726.ref004], [@pone.0225726.ref005]\].

The PVL exotoxin is not produced by all *S*. *aureus* strains, but have been detected in both methicillin-susceptible *S*. *aureus* (MSSA) and methicillin-resistant *S*. *aureus* (MRSA) strains \[[@pone.0225726.ref003]\]. The clinical presentation of PVL-positive MSSA and MRSA is very similar. It has also been shown that sub-inhibitory concentrations of beta-lactams increases PVL toxin production *in vitro* and that other antimicrobials that inhibit protein synthesis (e.g. rifampicin, clindamycin and linezolid) should be considered during treatment \[[@pone.0225726.ref006]\].

Methicillin-resistance is harboured on a mobile genetic element called the staphylococcal chromosome cassette *mec* (SCC*mec*). This element is genetically diverse and many types, subtypes and variants have been reported \[[@pone.0225726.ref007]\]. The cassette consists of three main structural components, namely: i) the cassette chromosome recombinase (*ccr*) gene complex, ii) the *mec* gene complex and iii) the joining (J) regions \[[@pone.0225726.ref008], [@pone.0225726.ref009]\]. The *ccr* gene complex encodes for site-specific recombinases that are responsible for the excision and integration of the SCC*mec* element into the staphylococcal chromosome \[[@pone.0225726.ref002], [@pone.0225726.ref007], [@pone.0225726.ref009]\]. The *ccr* gene complex provides the SCC*mec* element with mobility and consequently facilitates its transfer to other staphylococcal species \[[@pone.0225726.ref009]\]. The *mec* complex is responsible for conferring methicillin resistance. The *mec* gene complex consists of: i) a *mec*A/C gene, ii) its regulatory genes, the *mec*R1 and the *mec*I genes encoding for a signal transducer protein and repressor protein respectively and iii) various insertion sequences \[[@pone.0225726.ref007], [@pone.0225726.ref010]\]. A combination of the *ccr* gene complex with the *mec* gene class is used to assign the specific type of SCC*mec* element. Currently, thirteen SCC*mec* types (I-XIII) based on complete sequence data have been defined in MRSA \[[@pone.0225726.ref002], [@pone.0225726.ref011]--[@pone.0225726.ref013]\]; International Working Group on the Staphylococcal Cassette Chromosome elements (IWG-SCC) (2015) Available online: [http://www.sccmec.org](http://www.sccmec.org/)).

Typing of the SCC*mec* element is of epidemilogical importance to understand the evolution of MRSA. There are several methods (i.e. restriction enzyme digestion, PCR assays) available to determine the SCC*mec* type. The International Working Group for SCC*mec* elements currently recommends the method by Kondo and colleagues (2007) \[[@pone.0225726.ref012]\]. The only drawback of this assay is that it consists of six multiplex-PCR assays. However, the first two assays are generally sufficient to classify the majority of SCC*mec* elements \[[@pone.0225726.ref009]\]. The assay by Kondo and colleagues (2007) can easily detect novel *ccr* and *mec* gene complex combinations. \[[@pone.0225726.ref002], [@pone.0225726.ref012]\].

Healthcare-associated MRSA infections have previously been associated with SCC*mec* types I, II or III whereas community-acquired MRSA infections are linked to smaller SCC*mec* types IV, V, VI or VII \[[@pone.0225726.ref014]\] but epidemiological data is required to make this conclusion. A more recent report however, states that the traditional classification of healthcare- and community-associated MRSA is no longer appropriate because there is a notable overlap of identical clones between these two groups \[[@pone.0225726.ref015]\]. Previous work characterised the isolates in this study to determine the circulating SCC*mec* types \[[@pone.0225726.ref016]\]. However, a number of isolates produced an unknown SCC*mec* type as indicated by unidentified banding patterns. This study aimed to resolve unidentified SCC*mec* types using an alternative method. In addition, selected *S*. *aureus* isolates have been screened for the presence of the *luk*S/F-PV gene. Epidemiological data was used to classify isolates as healthcare- and community-associated and specific antimicrobial susceptibility profiles according to SCC*mec* type and PVL were reported.

Methods {#sec002}
=======

Case definition {#sec003}
---------------

A case of *S*. *aureus* bacteraemia was defined as the isolation of *S*. *aureus* from a blood culture. Isolates formed part of the GERMS-SA enhanced antimicrobial resistance surveillance study from January 2013 to January 2016. *S*. *aureus* isolates were from five sentinel centres in South Africa and sites represented six large academic hospitals from the Gauteng and the Western Cape provinces. A 21-day exclusion period was applied to avoid duplicate isolates of the organism from the same patient. In addition, the following clinical and epidemiological information were collected for each case: date of admission, previous hospitalisation or treatment and diagnosis. This information was used to define healthcare- and community-associated *S*. *aureus* infections. A case of community-associated bacteraemia was defined as a patient with *S*. *aureus* isolated from a blood culture specimen ≤ 48 hours of admission to a hospital and no contact within one year prior to the current episode of *S*. *aureus* infection with a healthcare facility (including prior surgery, dialysis and admission to a long term care facility). Healthcare-associated *S*. *aureus* infection was defined as a patient with *S*. *aureus* isolated \>48 hours after admission or with any prior healthcare contact. The patient's clinical diagnosis was used to select isolates for *luk*S/F-PV (i.e. PVL) screening.

Bacterial isolates and phenotypic assays {#sec004}
----------------------------------------

Isolates were submitted on Dorset transport media (Diagnostic Media Products, National Health Laboratory Service, South Africa) to the National Institute for Communicable Diseases (NICD), Johannesburg, South Africa. Each isolate was plated onto a 5% blood agar plate (Diagnostic Media Products, National Health Laboratory Service, South Africa) followed by organism identification and antimicrobial susceptibility testing using automated systems \[(VITEK II system (bioMèrieux, Marcy-l\'Etoile, France)/MALDI-TOF MS (Microflex, Bruker Daltonics, MA, USA) and MicroScan Walkaway system (Siemens, Sacramento, CA, USA), (Gram-positive panel PM33)\], respectively. An isolate was phenotypically non-susceptible if it had an oxacillin MIC of \>2 and a positive cefoxitin screening result. Interpretation of susceptibility was performed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines \[[@pone.0225726.ref017]\].

Genotypic assays {#sec005}
----------------

Total genomic DNA was extracted using a crude boiling method and used in the genotypic assays. [Fig 1](#pone.0225726.g001){ref-type="fig"} shows how isolates were selected for the genotypic assays. Prior work involved the screening for methicillin-resistance determinants, *mec*A and *mec*C on 484 phenotypically confirmed MRSA isolates. These isolates were typed by multiplex PCR to determine the circulating SCC*mec* types I to VI as described previously \[[@pone.0225726.ref018]\].

![Flowchart showing sample selection.\
The grey boxes show results that have been published previously \[[@pone.0225726.ref018]\]. Audit cases were defined as those cases that were identified according to the public healthcare sector Corporate Data Warehouse (CDW) (which houses records of patient details and laboratory results) but not received for processing in the laboratory. \* One isolate did not contain *mec*A or *mec*C and did not harbour a SCC*mec* element although it was phenotypically non-susceptible (oxacillin \>2, cefoxitin screen positive). This is possible as explained previously \[[@pone.0225726.ref019]\] possibly due to excision of the cassette (SCC*mec*) and/or *mec*A/C gene drop-out.](pone.0225726.g001){#pone.0225726.g001}

SCC*mec* typing of unidentified banding patterns {#sec006}
------------------------------------------------

An alternate SCC*mec* typing method was carried out by performing two conventional multiplex-PCR assays (i.e. *ccr* gene complex multiplex PCR assay detecting *ccr* gene complex 1 to 5 and the *mec* gene complex multiplex PCR assay detecting *mec* class A, B and C) using the G-Storm thermal cycler (Somerton Biotechnology Centre, Somerton, UK), the Qiagen Multiplex PCR kit (Qiagen, Nordrhein-Westfalen, Germany) and previously published primers \[[@pone.0225726.ref012]\]. The results of the *ccr* gene complex and the *mec* gene complex multiplex PCR assays were subsequently combined to assign a specific SCC*mec* type.

PCR screening for the *luk*S/F-PV gene {#sec007}
--------------------------------------

The presence of the *luk*S/F-PV gene was determined in MRSA and MSSA isolates from patients with a diagnosis of pneumonia or a lower respiratory tract infection, skin and soft tissue infection, bone infection and joint infection. Isolates were screened by a conventional PCR assay using the G-Storm thermal cycler, the Qiagen Multiplex PCR kit and previously published primers \[[@pone.0225726.ref020]\].

Statistical analysis {#sec008}
--------------------

Descriptive analyses were performed using Stata version 14 (StataCorp LP, College Station, Texas, USA). Categorical data were summarised using absolute frequencies and percentages.

Ethical approval {#sec009}
----------------

Ethical clearance was obtained from the University of the Witwatersrand Human Research Committee (Protocol number M10464).

Results {#sec010}
=======

SCC*mec* typing of unidentified banding patterns {#sec011}
------------------------------------------------

Only 51 isolates were tested with the *ccr* and the *mec* gene complex multiplex PCR assays, since a single isolate could not be retrieved from storage. A definite SCC*mec* type could not be determined for a three isolates, since all three of these isolates harboured two *ccr* gene complexes (*ccr* gene complex 1 and *ccr* gene complex 5) but was negative for all *mec* gene classes tested. A single isolate produced an indeterminate result and harboured either SCC*mec* type V or VII, since the assay by Kondo *et al*., 2007 \[[@pone.0225726.ref012]\] cannot distinguish between *mec* gene complex class C1 and C2. A further 44 isolates produced evidence of composite SCC*mec* elements as they harboured two *ccr* gene complexes and a single *mec* gene complex. These isolates were further interpreted as SCC*mec* type I-like (1B plus an additional *ccr* gene complex class 5) (86%, 38/44), SCC*mec* type II-like (2A plus an additional *ccr* gene complex class 5) (9%, 4/44) and SCC*mec* type III-like (3A plus an additional *ccr* gene complex class 5) (5%, 2/44). The SCC*mec* element type could clearly be assigned for two isolates only based on the *ccr* and *mec* gene complex combinations; these were SCC*mec* type II and IV. A new SCC*mec* combination (*ccr* gene complex class 5 and *mec* gene complex class A) was detected in a single isolate. Conclusive SCC*mec* types making use of both typing methods are seen in [Fig 2](#pone.0225726.g002){ref-type="fig"}.

![Final SCC*mec* type distribution among MRSA isolates 2013--2016.\
A total of 476 isolates are represented in this figure. One isolate could not be retrieved for testing, two isolates produced no SCC*mec* type, the *mec* class could not be identified for three isolates, one isolate could not be differentiated between types V or VII, and one isolate produced a new combination.](pone.0225726.g002){#pone.0225726.g002}

Epidemiological data were available for 463 of the 484 isolates that could be classified into healthcare- and community-associated *S*. *aureus* infection. Majority of these were healthcare-associated infections (92%, 428/463) followed by community-associated infections (8%, 35/463). [Table 1](#pone.0225726.t001){ref-type="table"} shows a breakdown of the SCC*mec* element types classified into healthcare- and community-associated infections.

10.1371/journal.pone.0225726.t001

###### Final SCC*mec* type distribution among MRSA isolates from 2013 to 2016 and its association between origin of the infection (i.e. healthcare- or community associated).

![](pone.0225726.t001){#pone.0225726.t001g}

  ----------------------------------------------------------------------------------
                           Healthcare-associated n/463 (%)   Community-associated\
                                                             n/463 (%)
  ------------------------ --------------------------------- -----------------------
  SCC*mec* type I          0                                 1 (0.2)

  SCC*mec* type II         43 (9)                            0

  SCC*mec* type III        218 (47)                          9 (2)

  SCC*mec* type IV         116 (25)                          19 (4)

  SCC*mec* type V          2 (0.4)                           0

  SCC*mec* type VI         3 (0.7)                           1 (0.2)

  SCC*mec* type V or VII   1 (0.2)                           0

  SCC*mec* type III-like   2 (0.4)                           0

  SCC*mec* type II-like    4 (0.9)                           0

  SCC*mec* type I-like     33 (7)                            4 (0.9)

  New combination          1 (0.2)                           0
  ----------------------------------------------------------------------------------

A single isolate could not be retrieved for testing, three isolates in which the *mec* gene class could not be detected were classified as healthcare-associated (n = 2) and community-associated (n = 1) and two isolates that produced no SCC*mec* banding pattern were classified as healthcare-associated.

Antimicrobial susceptibility testing and SCC*mec* types {#sec012}
-------------------------------------------------------

[Table 2](#pone.0225726.t002){ref-type="table"} shows AST data classified by the predominant SCC*mec* element types. Majority of the isolates were multidrug-resistant as indicated by their non-susceptibility to most of the antimicrobial agents. The p-value was calculated between susceptible (S) and the non-susceptible (I and R) isolates collectively and was significant for all antimicrobial agents.

10.1371/journal.pone.0225726.t002

###### Susceptibility of antimicrobial agents in MRSA isolates.

![](pone.0225726.t002){#pone.0225726.t002g}

                                  Number of isolates for which MIC value was:                    
  ------------------------------- --------------------------------------------- ----- ----- ---- ---------
  Ciprofloxacin                                                                                  
  ≤ 1 (S)                         \-                                            3     13    32   \<0.001
  2 (I)                           \-                                            \-    1     2    
  \>2 (I)                         43                                            233   131   4    
  ≥4 (R)                          \-                                            \-    \-    \-   
  Clindamycin                                                                                    
  ≤0.5 (S)                        4                                             212   139   36   \<0.001
  1--2 (I)                        \-                                            3     \-    \-   
  \>2 (I)                         39                                            21    6     2    
  ≥4 (R)                          \-                                            \-    \-    \-   
  Erythromycin                                                                                   
  ≤0.5 (S)                        \-                                            1     61    \-   \<0.001
  1-4(I)                          \-                                            \-    5     1    
  \>4 (I)                         43                                            233   79    37   
  ≥8 (R)                          \-                                            1     \-    \-   
  Gentamicin                                                                                     
  ≤4 (S)                          35                                            3     31    3    \<0.001
  8 (I)                           1                                             \-    4     8    
  \>8 (I)                         7                                             232   110   \-   
  ≥16 (R)                         \-                                            \-    \-    \-   
  Rifampicin                                                                                     
  ≤ 1 (S)                         39                                            219   32    29   \<0.001
  2 (I)                           \-                                            3     \-    \-   
  \>2 (I)                         3                                             14    112   1    
  ≥4 (R)                          \-                                            \-    1     \-   
  Tetracycline                                                                                   
  ≤4 (S)                          39                                            6     31    34   \<0.001
  8 (I)                           1                                             1     \-    2    
  \>8 (I)                         3                                             228   114   2    
  ≥16 (R)                         \-                                            \-    \-    \-   
  Trimethoprim/sulfamethoxazole                                                                  
  ≤2/38 (S)                       38                                            9     28    37   \<0.001
  ≥4/76                           4                                             225   106   1    

MIC: Minimum inhibitory concentration.

Interpretation of results was done according to CLSI guidelines \[[@pone.0225726.ref017]\]; S: susceptible, I: Intermediate resistance, R: Resistant.

\*The p-value was calculated between susceptible (S) and the non-susceptible (I and R) isolates collectively.

Multidrug resistance was defined as non-susceptibility to at least one antimicrobial agents in three or more categories \[[@pone.0225726.ref021]\].

PCR screening for the *luk*S/F-PV gene {#sec013}
--------------------------------------

Of a total of 1641 isolates, 768 (47%) isolates were selected for screening for the *luk*S/F-PV gene based on the type of infection. Isolates from patients diagnosed with skin and soft tissue infection (80%, 617/768), pneumonia/lower respiratory tract infection (8%, 62/768), bone infection (2%, 15/768) or joint infection (10%, 74/768) were selected.

Seven isolates could not be retrieved and were therefore not tested for the presence of *luk*S/F-PV. The presence of the PVL toxin was seen in 14% (108/761) of the isolates tested; 25% (27/108) in MRSA and 75% (81/108) in MSSA. Majority of PVL-positive *S*. *aureus* cases were from the Gauteng (75%, 81/108) followed by the Western Cape province (25%, 27/108). Majority of these infections were from patients with skin and soft tissue infection (70%, 75/108), followed by pneumonia/lower respiratory tract infection (21%, 23/108), joint infection (8%, 9/108) and bone infection (1%, 1/108) (p\<0.0001).

Eleven (41%) and 13 (48%) of 27 MRSA isolates that were PVL*-*positive were associated with SCC*mec* types III and IV respectively with just one isolate each for types I, V and VI ([Table 3](#pone.0225726.t003){ref-type="table"}).

10.1371/journal.pone.0225726.t003

###### Presence of SCC*mec* types and prevalence of the Panton-Valentine Leukocidin gene in MRSA isolates (n = 27).

![](pone.0225726.t003){#pone.0225726.t003g}

  SCCmec type                         Type of infection                PVL-positive strains (n, %)
  ----------------------------------- -------------------------------- -----------------------------
  II                                  Skin and soft tissue infection   1 (4)
  III                                 Skin and soft tissue infection   8 (30)
  Joint Infection                     2 (7)                            
  Lower respiratory tract infection   1 (4)                            
  IV                                  Skin and soft tissue infection   8 (30)
  Joint Infection                     1 (4)                            
  Bone Infection                      1 (4)                            
  Lower respiratory tract infection   3 (10)                           
  V                                   Joint Infection                  1 (4)
  VI                                  Joint Infection                  1 (4)

[Table 4](#pone.0225726.t004){ref-type="table"} shows the antimicrobial susceptibility profiles for PVL-positive *S*. *aureus* isolates according to patient's diagnosis.

10.1371/journal.pone.0225726.t004

###### Antimicrobial susceptibility profiles for PVL-positive *S*. *aureus* isolates according to patient's diagnosis.

![](pone.0225726.t004){#pone.0225726.t004g}

  Antimicrobial agents MIC range (μg/mL)               Patient's diagnosis            
  ---------------------------------------------------- --------------------- ---- --- ---
  **Oxacillin resistant /cefoxitin screen positive**   17                    4    1   5
  **Trimethoprim/sulfamethoxazole**                                                   
  **≤2/38 (S)**                                        57                             
  **\>2.38 (R)**                                       1                              
  **4/76 (R)**                                         2                              
  **\>4/76 (R)**                                       15                             
  **Clindamycin**                                                                     
  **≤0.25 (S)**                                                              23   1   8
  **0.5 (S)**                                                                0    0   1
  **1 (R)**                                                                  0    0   0
  **\>2 (R)**                                                                0    0   0
  **Daptomycin**                                                                      
  **≤1 (S)**                                                                      1   9
  **Linezolid**                                                                       
  **≤1 (S)**                                                                 15   0   3
  **≤2(S)**                                                                  0    0   
  **2 (S)**                                                                  8    1   6
  **Rifampicin**                                                                      
  **≤0.5 (S)**                                                               19       
  **≤1 (S)**                                                                 1        
  **2 (I)**                                                                  3        
  **\>2 (R)**                                                                0        

S--Susceptible, I--Intermediate resistance, R--Resistant

Shaded grey boxes indicate that the antimicrobial agents is not the recommended treatment of choice.

Epidemiological data for five isolates were missing. Of 103 PVL-positive isolates, 56% (58/103) were classified as healthcare-associated *S*. *aureus* infection followed by 44% (45/103) that were community-associated infection.

Discussion {#sec014}
==========

In the current study, MRSA accounted for 30% of the total staphylococcal bacteraemia infections. SCC*mec* element typing was performed on these MRSA isolates, but 11% could not be typed by the multiplex PCR assay described by Milheiriço and colleagues (2007) \[[@pone.0225726.ref022]\]. An alternate SCC*mec* typing method was employed to further classify untypeable SCC*mec* elements based on *ccr* and *mec* gene complex combinations. In addition, the association between antimicrobial susceptibility profiles, specific SCC*mec* types, the epidemiological point of acquisition (i.e. healthcare-associated vs. community-acquired infection) and the presence of the PVL toxin were reported.

The study showed that the majority of untypeable isolates harboured more than one *ccr* gene complex. This indicates the possibility of composite SCC*mec* elements circulating in MRSA strains in South Africa. Sequencing of the complete element would be required to determine if these elements represent a single SCC*mec* element with two *ccr* gene complexes or if the element consists of two separate integrated SCC*mec* elements \[[@pone.0225726.ref023]\]. It is also important to note that the method published by Kondo and colleagues (2007) \[[@pone.0225726.ref012]\] possesses some limitations. The *ccr* gene complex multiplex-PCR assay cannot detect *ccr* gene complex 6 to 9, hence SCC*mec* type X (*ccr* gene complex 7), SCC*mec* type XI (*ccr* gene complex 8), SCC*mec* XII (*ccr* gene complex 9) and SCC*mec* type XIII (*ccr* gene complex 9) would not have been detected. Furthermore, the *mec* gene complex multiplex-PCR assay cannot distinguish between *mec* class C1 and C2 and only detects the *mec* gene complex C resulting in not being able to distinguish between SCC*mec* type V (*mec* gene complex C2) and SCC*mec* type VII (*mec* gene complex C1). This assay also does not detect the *mec* gene complex E and therefore SCC*mec* type XI (*mec* gene complex E) would not be detected.

While this method did not definitively classify all the unknown isolates into clearly defined types, it showed that majority of these isolates were not the conventional SCC*mec* types. It should be noted that only two of the six multiplex-PCR assays were performed; however the first two assays are generally sufficient to classify the majority of SCC*mec* elements \[[@pone.0225726.ref009]\]. For this reason we performed only the two PCR assays. Types I, II and III are thought to be related to healthcare-associated infections and types IV, V and VI with community-associated infections \[[@pone.0225726.ref014]\]; this was the case for a large number of the isolates except for 116 SCC*mec* type IV isolates which were classified as healthcare-associated. A further few did not strictly behave as traditionally expected. A more recent report however, states that the traditional classification of healthcare-associated and community-associated MRSA is no longer appropriate because there is a notable overlap of identical clones between these two groups. This may confirm the limitation in defining healthcare-associated and community-associated infections based on SCC*mec* types and that traditionally considered community-associated isolates have the potential to establish themselves as healthcare-associated pathogens and vice versa. \[[@pone.0225726.ref015]\].

The results obtained demonstrate that majority of the *S*. *aureus* isolates displaying resistance to methicillin were non-susceptible to ciprofloxacin, erythromycin, gentamicin, rifampicin, tetracycline and trimethoprim/sulfamethoxazole while susceptible to clindamycin only, indicating that multiple resistance genes are present ([Table 2](#pone.0225726.t002){ref-type="table"}). A previous 2010 Swiss study \[[@pone.0225726.ref024]\] showed some differences in their findings although the sample number was small (N = 78); 60% were resistant to ciprofloxacin compared to 90% in our findings, 33% were resistant to erythromycin compared to 87% in our study and 18% were resistant to gentamycin as compared to 83% in our study. Rifampicin and trimethoprim/sulfamethoxazole were resistant in none of the isolates from the Swiss study; however our findings showed that 30% and 75% were resistant respectively. Clindamycin displayed 15% resistance in our study and this was comparable to the Swiss study where 16% of the isolates were resistant. As in our study, erythromycin resistance was also quite high in 91.6% (n = 564) of the isolates in another study \[[@pone.0225726.ref025]\] but comparable to the Swiss study in another study (32.8%) \[[@pone.0225726.ref026]\]. This latter study looked at nasal colonisation with MRSA from the nasal secretion from children in day-care centres. Resistance to ampicillin was high (80%) but resistance to ciprofloxacin, clindamycin and tetracycline was low (7.1%, 7.1% and 4.3% respectively) \[[@pone.0225726.ref026]\]. The differences in the results between studies may be attributed to prescription practices which vary between hospitals and geographical locations.

A small American study (N = 60) showed that overall the healthcare-associated SCC*mec* type II isolates were resistant to more antimicrobials than the community-associated type IV isolates \[[@pone.0225726.ref027]\]. This was also seen in another small (N = 65) Polish study in 2013 \[[@pone.0225726.ref028]\]. The opposite was true in our study where type IV isolates were resistant to more antibiotics than the type II isolates. It should however be noted that in our study 116 SCC*mec* type IV isolates were classified as healthcare---associated infections and not community-associated infections.

Less than 50% of the isolates were screened for the presence of the PVL toxin as indicted by patient diagnosis; the presence of which was seen in 14% (n = 108/761) of the isolates tested; 25% (27/108) in MRSA and 75% (81/108) in MSSA. A 2012 Turkish study also showed a low proportion (2.2%, n = 10) of PVL-positive isolates, all of which were MSSA \[[@pone.0225726.ref004]\]. In the current study, 11 (41%) and 13 (48%) of 27 MRSA isolates that were PVL*-*positive were associated with SCC*mec* types III and IV respectively with just one isolate each for types I, V and VI. A previous study showed that 81.5% (22/27) PVL-positive isolates were associated with type IV elements but none of the type I, II or III elements detected were associated with the presence of the *luk*S/F-PV gene \[[@pone.0225726.ref029]\]. Another study that further characterised type IV isolates showed that these isolates were PVL-positive \[[@pone.0225726.ref030]\]. Isolates of *S*. *aureus* harbouring PVL are often because of community-associated infections \[[@pone.0225726.ref004]\]; however our findings showed that 56% were classified as healthcare-associated *S*. *aureus* infection followed by 44% that were community-associated infection. This was in contrast to a 2010 Swiss study where a high proportion (87%) of community-associated types IV and V among their PVL-positive strains was demonstrated \[[@pone.0225726.ref024]\]. A majority (48%) of the PVL*-*positive isolates were associated with SCC*mec* type IV ([Table 3](#pone.0225726.t003){ref-type="table"}) followed by type III (41%) with only one each for types II, V and VI; this was consistent with the 2007 American study where 23 of 25 SCC*me*c type IV isolates were PVL-positive compared to the type II elements (n = 34) which did not harbour the gene \[[@pone.0225726.ref027]\], as well as with a 2013 Polish study where all the type IV isolates were PVL-positive (9/9) and none of the type II isolates (0/16) harboured the gene. In this latter study only three of 40 type III isolates were positive for PVL \[[@pone.0225726.ref028]\]. All of these differences highlight the evolving nature of *S*. *aureus* and variations in clones as a result of evolution is evident from one geographical region to another.

According to a recent publication \[[@pone.0225726.ref003]\] the recommended treatment of choice for PVL-positive *S*. *aureus* infections are as follows; skin and soft tissue infections: Trimethoprim / sulfamethoxazole, bone and joint infections: flucloxacillin combined with clindamycin for MSSA and daptomycin combined with linezolid for MRSA, and pneumonia: clindamycin, linezolid or rifampicin. When we further analysed the antimicrobial susceptibility profiles of the PVL-positive isolates, we found that the treatment of choice as recommended by Saeed *et*. *al*., \[[@pone.0225726.ref003]\] would be ideal for treating *S*. *aureus* skin and soft tissue infections and pneumonia as indicated by the high number of susceptible isolates to each of the antimicrobial agents. The ten PVL-positive isolates from patients with bone and joint infections were also susceptible to all antibiotics except for oxacillin. This is encouraging as it offers available treatment options.

This study aimed to resolve unidentified SCC*mec* types using an alternative method. While this method did not definitively classify all the unknown isolates into clearly defined types, it showed that majority of these isolates were not the conventional SCC*mec* types. Majority of the *S*. *aureus* isolates displaying resistance to methicillin were non-susceptible most antimicrobial agents indicating that multiple resistance genes are present in our population. The presence of PVL more prevalent in MSSA and was seen in small percentage of isolates indicating a low proportion of this exotoxin in our population.
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We would appreciate receiving your revised manuscript by October 28th. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Davida S. Smyth, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. In ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study. Specifically, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

Additional Editor Comments (if provided):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors report in this manuscript an analysis and findings with the S. aureus strains isolated from blood of patients between 2013 to 2016 in South Africa. Majority of these samples appear to come from the patients with skin and soft tissue infections. The authors have made an attempt to classify the S. aureus strains as MRSA or MSSA. The MRSA strains have been further assigned into different SCCmec complexes. Some isolates could not be assigned to a specific SCCmec complex using common approaches so the authors have used additional molecular approaches. The authors have also made an effort to detect the presence of lukS/F-PV gene among the S. aureus isolates and determine the resistance to various antibiotics for the MRSA isolates. Overall, the manuscript is poorly written and is confusing and doesn't provide any clear picture.

Major issues:

1\. The authors state the title of the manuscript as 'Investigation of virulence factors.....". The manuscript has little to do with an investigation of the virulence factors. This is a misleading title.

2\. Same results are presented repeatedly with different percentages in different contexts. Like percent of MRSA and MSSA that were lukS/F-PV positive. It is then presented as among the lukS/F-PV how many of them are MRSA and how many of them are MSSA. It is unclear what the authors are trying to accomplish by stating same facts in two different ways. Some of these facts are also presented in Tables.

3\. Lines 329-324: It is relatively accepted that HA-MRSA are resistant to more antibiotics compared to CA-MRSA isolates. Authors find a bit different results but no real explanation.

4\. Authors also report much higher HA-MRSA strains to be lukS/F-PV positive. Is it possible that the authors are using a relatively loose metric to classify the isolates as CA-MRSA or HA-MRSA.

5\. Authors repeatedly mention in the discussion section that their results are different than what has been reported in the literature but provide no comment on this except stating that the published study was based on small sample size.

6\. The take home message of this manuscript is unclear.

Minor issues:

1\. What is GERM-SA?

2\. Line 115: Why not say from January 2013 to January 2016?

3\. Line 117: Why the 21-day exclusion rules out duplicate isolation?

4\. Lines 239-242: Very unclear the way it is stated. What does authors mean by '....considered to potentially harbor the lukS/F-PV gene?"

5\. Lines 243-245: Why not simplify as "27 of 394 MSSA strains possessed lukS/F-PV while 81 of the 374 MSSA possessed this gene."

Reviewer \#2: Minor comments

Lines 133-139: I suggest this (Each isolate was plated onto a 5% blood agar plate (Diagnostic Media Products, National Health Laboratory Service, South Africa) followed by organism identification and antimicrobial susceptibility testing using automated systemsVITEK II system (bioMèrieux, Marcy l\'Etoile, France)/MALDI-TOF MS (Microflex, Bruker Daltonics, MA, USA) and MicroScan Walkaway system (Siemens, Sacramento, CA, USA), (Gram-positive panel PM33) respectively).

Lines 152: You have to explain the screening methods of methicillin resistant briefly in the main text as you have shown in Fig 1. In the section bacterial isolates and phenotypic assays

Lines 164: You have to add in the supplementary section the primers of multiplex PCR assays.

Lines 412,430,426: Please correct your references.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

1 Oct 2019

Dear Editor

Thank you for considering the manuscript: "Investigation of virulence factors: SCCmec types and the Panton-Valentine Leukocidin exotoxin in South African blood culture Staphylococcus aureus surveillance isolates, 2013-2016" for publication.

The authors have addressed the reviewer's comments as follows:

Reviewer 1

Major issues:

1\. The authors state the title of the manuscript as 'Investigation of virulence factors.....". The manuscript has little to do with an investigation of the virulence factors. This is a misleading title.

The title has been changed to "Unconventional SCCmec types and low prevalence of the Panton-Valentine Leukocidin exotoxin in South African blood culture Staphylococcus aureus surveillance isolates, 2013-2016" which indicates the findings in this study.

2\. Same results are presented repeatedly with different percentages in different contexts. Like percent of MRSA and MSSA that were lukS/F-PV positive. It is then presented as among the lukS/F-PV how many of them are MRSA and how many of them are MSSA. It is unclear what the authors are trying to accomplish by stating same facts in two different ways. Some of these facts are also presented in Tables.

The authors agree with the reviewer's comment and have removed the statement showing the percentage of MRSA and MSSA that were selected for PVL-screening (line 240-241). Only the percentage of MRSA and MSSA in the PLV-positive group are shown (lines 246-247).

3\. Lines 329-324: It is relatively accepted that HA-MRSA are resistant to more antibiotics compared to CA-MRSA isolates. Authors find a bit different results but no real explanation.

Although the findings from this study show that the type IV isolates were more resistant than type II isolates, a large number of these type IV isolates were indeed classified as HA-MRSA which is in keeping with other studies that showed that their HA strains were more resistant. This is mentioned in the latter part of the paragraph (lines 338-340). Differences in results could be attributed to clonal evolution and variations in different geographical locations -- this has been included in lines 361-363.

4\. Authors also report much higher HA-MRSA strains to be lukS/F-PV positive. Is it possible that the authors are using a relatively loose metric to classify the isolates as CA-MRSA or HA-MRSA.

The criteria used to classify CA- and HA-MRSA infections are described in the Methods section (Case Definition) and are acceptable criteria for defining these infections. This finding could be attributed to variations is different geographical locations (lines 361-363). However, it is also mentioned that there may be overlap of identical clones between these two groups (lines 305-307). This could potentially be another reason for this finding.

5\. Authors repeatedly mention in the discussion section that their results are different than what has been reported in the literature but provide no comment on this except stating that the published study was based on small sample size.

Possible explanations have been included (lines 320-330 and 361-363).

6\. The take home message of this manuscript is unclear.

The last paragraph in the discussion addresses this -- we have found that these unknown SCCmec types are largely unconventional and cannot be clearly defined. Additionally, the prevalence of PVL was low and more common in MSSA.

Minor issues:

1\. What is GERM-SA?

This is a national surveillance platform at the National Institute for Communicable Diseases in South Africa. Previously, this was an acronym for the Group for Enteric, Respiratory and Meningeal Surveillance in South Africa. This platform was subsequently expanded to include other diseases such as those related to healthcare-associated infections. While GERMS-SA is still used, it is no longer referred to as the Group for Enteric, Respiratory and Meningeal Surveillance in South Africa. For this reason, it was not included in the manuscript.

2\. Line 115: Why not say from January 2013 to January 2016?

This has been corrected as suggested by the reviewer.

3\. Line 117: Why the 21-day exclusion rules out duplicate isolation?

A surveillance case definition of 21 days was applied to exclude duplicates i.e. to exclude infection caused by the same S. aureus strain. This is because if the patient acquired a subsequent blood stream infection within 21 days, the infection would probably be due to the same S. aureus strain. One would expect, that, provided adequate treatment was administered, the specific S. aureus infection would have been treated within this time-frame. Any infection with S. aureus after 21 days is considered to be a new infection.

4\. Lines 239-242: Very unclear the way it is stated. What does authors mean by '....considered to potentially harbor the lukS/F-PV gene?"

It is previously stated that PVL is linked to these infection types (line 59-62). Therefore no further explanation is required and this statement has been removed.

5\. Lines 243-245: Why not simplify as "27 of 394 MSSA strains possessed lukS/F-PV while 81 of the 374 MSSA possessed this gene."

As mentioned in response to comment 2 (major issues), the statement showing the percentages and numbers of MRSA and MSSA that were selected for PVL-screening (line 240-241) have been removed and we have decided to focus on the PVL-positive group. For this reason, the denominator used is that of the PVL-positive isolates.

Reviewer 2

Minor Issues:

1\. Lines 133-139: I suggest this (Each isolate was plated onto a 5% blood agar plate (Diagnostic Media Products, National Health Laboratory Service, South Africa) followed by organism identification and antimicrobial susceptibility testing using automated systemsVITEK II system (bioMèrieux, Marcy l\'Etoile, France)/MALDI-TOF MS (Microflex, Bruker Daltonics, MA, USA) and MicroScan Walkaway system (Siemens, Sacramento, CA, USA), (Gram-positive panel PM33) respectively).

This has been corrected as per the reviewer's suggestion.

2\. Lines 152: You have to explain the screening methods of methicillin resistant briefly in the main text as you have shown in Fig 1. In the section bacterial isolates and phenotypic assays

This has been included in the text as per the reviewer's recommendation.

3\. Lines 164: You have to add in the supplementary section the primers of multiplex PCR assays.

As the method and primers used are well-known and published, the list of primers were not included. However, the method and primers have been referenced (line 170).

4\. Lines 412,430,426: Please correct your references.

The references have been corrected as requested.

Moreover, the grammar and spelling throughout the manuscript have been examined and addressed.

Corresponding author:

Dr. Ashika Singh-Moodley

Senior Medical Scientist

Centre for Healthcare-associated infections, Antimicrobial Resistance and Mycoses

Antimicrobial Resistance Laboratory and Culture Collection

1 Modderfontein Road, Sandringham

Private Bag X4, Sandringham, Johannesburg 2131

South Africa

Tel: +27 (0)11 555 0342 \| Fax: +27 (0) 11 555 0430

<ashikas@nicd.ac.za> / <singh.ashika@gmail.com>

I wish to thank you for the opportunity to re-submit this manuscript that investigates SCCmec types and the Panton-Valentine Leukocidin exotoxin in South African blood culture Staphylococcus aureus surveillance isolates and I hope that our attempts at addressing the comments are acceptable.

Kind regards

Ashika Singh-Moodley
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PONE-D-19-23434R1

Dear Dr. Singh-Moodley, 

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Davida S. Smyth, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: Yes: Dr Raspail Carrel Founou
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Unconventional SCCmec types and low prevalence of the Panton-Valentine Leukocidin exotoxin in South African blood culture Staphylococcus aureus surveillance isolates, 2013-2016.

Dear Dr. Singh-Moodley:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Davida S. Smyth

Academic Editor

PLOS ONE
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